Product Information
Registration Status: ActivePOLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG is approved to be sold in Singapore with effective from 2020-09-08. It is marketed by ROCHE SINGAPORE PTE LTD, with the registration number of SIN16007P.
This product contains Polatuzumab Vedotin 140 mg in the form of INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION. It is approved for INTRAVENOUS use.
This product is manufactured by BSP Pharmaceuticals S.p.A(Primary Packager) in ITALY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Polatuzumab Vedotin has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Lymphoma, B-Cell, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, Lymphoma, Follicular, Lymphoma, Follicular, Diffuse Large B-Cell Lymphoma, and Diffuse Large B-Cell Lymphoma, Lymphoma, Non Hodgkin, Lymphoma, Follicular, among others.
Active Ingredient/Synonyms
Polatuzumab Vedotin | Polatuzumab Vedotin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.